International Summit on Human Gene Editing

International Summit on Human Gene Editing
Name	International Summit on Human Gene Editing
Date	Various (2015, 2018, 2023)
Location	Washington, D.C., Hong Kong, London
Participants	Jennifer Doudna, Feng Zhang, David Baltimore, Emmanuelle Charpentier, Francis Collins
Organizers	U.S. National Academy of Sciences, U.S. National Academy of Medicine, Royal Society, Chinese Academy of Sciences

International Summit on Human Gene Editing. The International Summit on Human Gene Editing is a series of high-level global conferences convened to examine the scientific, ethical, and governance implications of CRISPR and related genome-editing technologies. Organized by leading international scientific academies, these summits bring together researchers, ethicists, policymakers, and patient advocates from around the world. The discussions have been pivotal in shaping the international dialogue on the responsible use of these powerful tools, particularly regarding human applications.

Background and Context

The rapid development of CRISPR-Cas9 as a precise and accessible gene-editing tool, pioneered by scientists like Jennifer Doudna and Emmanuelle Charpentier, created an urgent need for global discourse. Following early experiments in China and the United States, the scientific community recognized the potential for both profound therapeutic benefits and significant ethical risks, such as germline modifications. This context was framed by earlier debates on recombinant DNA at the Asilomar Conference and the evolving landscape of bioethics following the Human Genome Project. The organizing bodies, including the U.S. National Academy of Sciences and the Royal Society, sought to establish an international forum akin to those for climate change or nuclear non-proliferation.

Key Summits and Meetings

The first summit was held in Washington, D.C. in December 2015, co-hosted by the U.S. National Academy of Medicine, the Chinese Academy of Sciences, and the Royal Society. A second critical summit took place in Hong Kong in November 2018, which gained global notoriety following the announcement by He Jiankui of the birth of the first gene-edited babies. The third major international gathering was convened in London in March 2023, organized again by the Royal Society, the Academy of Medical Sciences, and other global partners. These events were often held in parallel with related meetings by the World Health Organization and the International Bioethics Committee.

Major Declarations and Statements

The 2015 summit concluded that it would be "irresponsible" to proceed with clinical use of germline editing without broader societal consensus. The 2018 Hong Kong summit, responding directly to the He Jiankui controversy, issued a stronger statement condemning the work as a failure of self-regulation and a violation of international norms. It called for a translational pathway from laboratory research to clinical application. These summits influenced subsequent reports by the U.S. National Academies and the WHO Expert Advisory Committee on developing global standards and a registry for human genome editing research.

Scientific and Ethical Discussions

Core scientific discussions focused on advances in base editing, prime editing, and off-target effects, as presented by researchers like Feng Zhang and David Liu. Ethical debates were intense, centering on the morality of human enhancement, the concept of genetic inequality, and the rights of future generations. The specter of eugenics was frequently invoked, with comparisons drawn to historical abuses. The distinction between somatic cell therapy for diseases like sickle cell anemia and heritable germline modifications was a fundamental fault line in all dialogues.

Global Policy and Regulatory Impact

The summits have significantly influenced national and international policy frameworks. They provided direct impetus for the World Health Organization to establish its global registry and governance recommendations. Many countries, including the United Kingdom (via the Human Fertilisation and Embryology Authority), Japan, and Germany, have cited summit conclusions in shaping or tightening their own legislative and regulatory approaches. The discussions also informed the stance of major funding bodies like the National Institutes of Health and the European Commission on supporting certain types of research.

Notable Participants and Organizations

Prominent scientific participants have included Nobel Prize laureates Jennifer Doudna, Emmanuelle Charpentier, and David Baltimore, alongside leading researchers George Church and Robin Lovell-Badge. Ethicists and policy figures such as Alta Charo and Françoise Baylis have been central voices. Key organizing and participating institutions beyond the hosts include the Max Planck Society, the African Academy of Sciences, the Wellcome Trust, and the Hinxton Group. Representation from patient advocacy groups and civil society organizations has been a consistent feature of the summits' panels and audiences.

Category:Science and technology conferences Category:Bioethics Category:Genetics